This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The basis of the analysis of the clinical study was intention to treat. The primary health outcome was the change in FEV1. The secondary outcomes included quality of life and the number of pulmonary exacerbations, which were defined using an outlined protocol for respiratory tract infection. Adherence to treatment was monitored in two ways. The patients were asked to return all unused bottles of HS and used vials of rhDNase, and they also recorded the treatment doses taken for each trial drug in a patient diary.
Effectiveness results
There was a mean increase in FEV1 from baseline of 16 (25%) for patients receiving daily rhDNase, 14 (23%) for patients receiving alternate rhDNase, and 3 (21%) for patients receiving HS.
Comparing the mean FEV1, there was a mean advantage of 8% (95% confidence interval, CI: 2 -14; p=0.01) for daily rhDNase over HS, but none for daily rhDNase compared with alternate day rhDNase (2%, 95% CI: -4 -9; p=0.55).
There were variations to individual responses to treatments. Twenty-six of the 40 children responded better with daily rhDNase than with HS.
There was no evidence of differences in the quality of life, or in the occurrence of pulmonary exacerbations, between the treatments.
Clinical conclusions
The authors concluded that their study found that daily rhDNase was more effective than HS. In addition, administering rhDNase on alternate days was as effective as administering it on a daily basis.
Measure of benefits used in the economic analysis
The primary outcome measure in the economic analysis was the change in FEV1. The secondary outcome measures included quality of life and the number of pulmonary exacerbations. Quality of life was measured using the quality of well-being scale. The number of exacerbations was defined using an outlined protocol for respiratory tract infections.
Direct costs
Discounting was not carried out since the costs were incurred less than 2 years. The costs and the quantities were reported separately. All health care resources including hospital contacts (inpatient, outpatient and ward review), radiological investigations, blood tests, drug use and the use of community services (including community nurse, physiotherapist and general practitioner) were assessed. The study was conducted from a health service perspective. The quantities were estimated from actual data. The source of the resources used was the patients' hospital notes and diaries. The cost data were collected from the relevant departments. The finance departments at the three hospitals also provided information on the total costs of consumables and overheads on the ward or department where CF patients
The authors justified their choice of the comparator since it represented a valid treatment option in their setting. You should decide if the comparator represents a valid option in your setting.
Validity of estimate of measure of effectiveness
The analysis used a prospective randomised controlled crossover design, which was appropriate for the study question.
The study sample appears to have been representative of the study population. The internal validity of the study is likely to be quite high due to the randomisation process. The authors indicated that there was evidence that the period between the treatments was sufficient for a complete washout. If the washout period was insufficient it would be difficult to establish the effectiveness of each separate treatment. Power calculations were conducted to ensure that the sample size was large enough to detect statistical significance.
Validity of estimate of measure of benefit
The measure of benefit was obtained directly from the effectiveness analysis. The authors indicated that the details of the health economic assessment were in a study reported elsewhere (see Other Publications of Related Interest).
Validity of estimate of costs
All the categories of costs relevant to the perspective adopted (the health service) appear to have been included in the analysis. The resource use quantities were taken from a single study and statistical analyses of the quantities were undertaken. The indirect costs were not included as the perspective of the study only considered the direct costs. The authors highlight the fact that taking a societal perspective (i.e. including indirect costs) would be unlikely to change the results. Both statistical and sensitivity analysis were undertaken on the costs. Discounting was not undertaken since all the costs were incurred in a period of 12 months. The dates to which the prices related were reported. In addition, the costs and the quantities were reported separately. These factors enhance the reproducibility of the results in other settings.
Other issues
The authors made appropriate comparisons of both the effectiveness and study results with those from other studies. In addition, the issue of generalisability was addressed. The authors do not appear to have presented their findings selectively and their conclusions reflect the scope of the analysis. The authors reported a shortcoming of their study in that it would have required about four times as many patients for the observed difference in cost to have been found statistically significant. Power calculations were conducted to ensure that the study was powered to detect differences in the effectiveness measures, but not in the costs.
Implications of the study
The authors indicated that there is a need for further research to assess the long-term costs and consequences of the respective strategies. In particular, to examine the relative use of hospital resources for larger groups of patients over a longer period of time. They also highlighted the fact that further studies may benefit from stating in advance what constitutes an important differential in the total cost, and then using a measure of variability from the study to perform sample size calculations.
Source of funding
Funded by the NHS Technology Assessment Programme.
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